

Company Number: 4784475

21CEC PX Pharm Ltd

Company Accounts - Attachments List

Company Number: 4784475

5th Accounting Period – 06 April 2008 – 05 April 2009

- 1 Profit and Loss Account**
- 2 Balance Sheet**
- 3 Fixed Assets**
- 4 Bank Accounts**
- 5 Director's Report**

WEDNESDAY



AIKE2EHN

A22

28/10/2009

292

COMPANIES HOUSE

Company Number: 4784475

21CEC PX Pharm Ltd

Profit and Loss Account

Attachment 1 of Company Accounts

6th Accounting Period – 06 April 2008 – 05 April 2009

Profit and Loss Report

For The 6th Accounting Period : 06/04/2008 - 05/04/2009

Income:	Period (£)	Year to Date (£)
Sales	33,082.00	33,082.00
Sales – other	0.00	0.00
Bank interest (Gross)	192.00	192.00
INCOME	33,274.00	33,274.00
Purchases:		
Cost of Goods	17,109.00.00	17,109.00 .00
Materials	0.00	0.00
Agents Commission fees	0.00	0.00
COST OF SALES	17,109.00.00	17,109.00.00
GROSS PROFIT	16,165.00	16,165.00
Expenditure:		

Employee cost	0.00	0.00
Premises expenses	2,533.00	2,533.00
Repairs & Renewals	0.00	0.00
Administration expenses	6,853.00	6,853.00
Motor Expenses	1,340.00	1,340.00
Travel and subsistence	118.00	118.00
Advertising, promotion and entertainment	4851.00	4,851.00
Legal and Professional costs	0.00	0.00
Bad debit	0.00	0.00
Interest	0.00	0.00
Other finance charges	0.00	0.00
Depreciation and loss on sale	0.00	0.00
Other expenses	0.00	0.00
TOTAL EXPENSES	15,695.00	15,695.00
NET PROFIT / (LOSS)	470.00	470.00

Company Number: 4784475

21CEC PX Pharm Ltd

Balance Sheet

Attachment 2 of Company Accounts

6th Accounting Period – 06 April 2008 – 05 April 2009

Balance Sheet			Capital Account		
For The 6th Accounting Period : 06/04/2008 - 05/04/2009					
Fixed Assets					
Plant & Machinery	£249.99				
Computer Equipment	£2,954.84		Share Capital	EU 10,000.00 (=£8,598.75)	
Motor Vehicles	0.00		Capital Reserve	£15,510.74	
			CASH	£0.00	
			Profit/Loss	£470.00	
			Provision for Corporation Tax	£98.70	
Total	£3,204.83				
Current Assets				Total	£24,678.19
Stock	0.00				
Debtors	0.00				
Bank Accounts	£20,904.66			Capital Employed	£38,600.00
Total	£24,109.49				
Current Liabilities					
Current Liabilities	0.00				
Corporation Tax	£98.70				
Loans	0.00				
VAT payable	0.00				
Director's Loan	0.00				
Total	£98.70				

	Net Current Assets	£20,904.66		
	Net Assets	£20,904.66		

Audit Exemption Statement:

For the year ended 5 April 2009, the company was entitled to exemption under section 249A(1) of the Companies Act 1985. No members have required the company to obtain an audit of its accounts for the year in question in accordance with section 249B(2). The directors acknowledge their responsibility for: i) Ensuring the company keeps accounting records which comply with section 221; and ii) Preparing accounts which give a true and fair view of the state of affairs of the company as at the end of its profit and loss for the financial year in accordance with section 226, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the company.

Signed by



Dr. C. Bleasdale

Director

21CEC PX PHARM LTD.

Company Number: 4784475

21CEC PX Pharm Ltd

Fixed Assets

Attachment 3 of Company Accounts

6th Accounting Period – 06 April 2008 – 05 April 2009

Fixed Assets - Current items

<u>Purchased</u>	<u>Nominal Code</u>	<u>Product name</u>	<u>Details</u>	<u>Purchase Price</u>	<u>Action</u>
17/01/2004	FA002	Fridge/Freezer	SRL3216	£249.99	
05/08/2005	FA005	Computer Equipment	Laptop 2	£663.87	
12/04/2006	FA006	Computer Equipment	Computer x64	£1,050.00	
05/04/2007	FA007	Computer Equipment	Computer	£724.97	
10/09/2008	FA008	Computer Equipment	HP Business Desktop	£516.00	

Details of Fixed Asset – FA002	
Purchase Date	17/01/2004 (dd/mm/yyyy format)
Supplier Account	Iceland, Eastbourne
Nominal Code	FA002

Your reference	Expense2003		
Details	Fridge / Freezer (Samsung SRL3216)		
Purchase Price (Gross) £	£249.99		
Net Price £	£206.24		
Payment history	Date	Amount	Account
	17/01/2004	£249.99 £	LloydsTSB VISA Card
			Action Paid
Make a payment			
Date Paid			
Amount Paid £			
Bank Account used			
Sale Details			
Sold Date			
Sale Amount £			
Bank Account used			
Capital Allowance			
Residual Amount £			
Allowance this Year £			
Depreciated Value £			

Details of Fixed Asset – FA005	
Purchase Date	05/08/2005 (dd/mm/yyyy format)
Supplier Account	Dabs.com, online
Nominal Code	FA005
Your reference	Expense2005
Details	Laptop

Purchase Price (Gross) £	£663.87 (inc. VAT)			
Net Price £				
VAT	VAT Rate: 17.5%			
Payment history	Date	Amount	Account	Action
	05/08/2005	£663.87 +Delivery £7.00 —£670.87.00	LloydsTSB VISA Card	Paid
Make a payment				
Date Paid				
Amount Paid £				
Bank Account used				
Sale Details				
Sold Date				
Sale Amount £				
Bank Account used				
Capital Allowance				
Residual Amount £	0.00			
Allowance this Year £				
Depreciated Value £	11,19.00			

Details of Fixed Asset – FA006	
Purchase Date	12/04/2006 (dd/mm/yyyy format)
Supplier Account	Active Computers, Bexhill
Nominal Code	FA006
Your reference	Expense2006
Details	PC
Purchase Price (Gross) £	£1,050.00

Net Price £			
VAT£	VAT Rate: 17.5% included		
Payment history	Date	Amount	Account
	12/04/2006	£1,050.00 £	Lloyds TSB Mastercard
Make a payment			
Date Paid			
Amount Paid £			
Bank Account used			
Sale Details			
Sold Date			
Sale Amount £			
Bank Account used			
Capital Allowance			
Residual Amount £			
Allowance this Year £			
Depreciated Value £			

Details of Fixed Asset – FA007			
Purchase Date	05/04/2007	(dd/mm/yyyy format)	
Supplier Account	HP Compaq		
Nominal Code	FA007		
Your reference	Expense2007		
Details	PC		
Purchase Price (Gross) £	£724.97		
Net Price £			
VAT£	VAT Rate: 17.5% included		
Payment history	Date	Amount	Account
	09/04/2007	£724.97 £	Lloyds TSB Mastercard
Make a payment			
Date Paid			

Amount Paid £	
Bank Account used	
Sale Details	
Sold Date	
Sale Amount £	
Bank Account used	
Capital Allowance	
Residual Amount £	
Allowance this Year £	
Depreciated Value £	

Details of Fixed Asset – FA008					
Purchase Date	10/09/2008	(dd/mm/yyyy format)			
Supplier Account	HP Compaq				
Nominal Code	FA008				
Your reference	Expense2008				
Details	PC				
Purchase Price (Gross) £	£516.00				
Net Price £					
VAT £	VAT Rate: 15.0% included				
Payment history	Date	Amount	Account Action		
	10/09/2008	£516.00 £	LloydsTSB Mastercard		
Make a payment					
Date Paid					
Amount Paid £					
Bank Account used					
Sale Details					
Sold Date					
Sale Amount £					
Bank Account used					
Capital Allowance					
Residual Amount £					

Allowance this Year £	
Depreciated Value £	

Company Number: 4784475

21CEC PX Pharm Ltd

Bank Accounts

Attachment 4 of Company Accounts

6th Accounting Period – 06 April 2008 – 05 April 2009

Bank Accounts – At the end of Accounts 2008 (5 April 2009)

<u>ACCOUNT NAME</u>	<u>ACCOUNT NUMBER</u>	<u>SORT CODE</u>	<u>BALANCE</u>	<u>BALANCE IN GBP £</u>
Lloyds TSB – GBP			£11,178.56	£11,178.56
Lloyds TSB - USD			\$12,147.90	\$12,147.90 (=£7,357.10)
Lloyds TSB - EURO			EU 2,755.06	EU 2,755.06 (=£2,369.00)
Lloyds TSB – GBP Business instant access account			NIL	NIL
CASH	£.00		NIL	NIL
Registered Capital - EU 10,000.			Total	£20,904.66
12. Aug. 2009 Exchange rate	£1 = \$1.65118 £1 = EU 1.16296			

21CEC PX Pharm Ltd

Director's Report

Attachment 5 of Company Accounts

6th Accounting Period – 06 April 2008 – 05 April 2009

Director's Report

This is the 6th accounting period (6 April 2008 – 5 April 2009) of our company 21CE PX PARM LTD (21CECPX) – A private limited pharmaceuticals company registered in England.

In this Director's Report for 2008 I would highlight the business situation of 21CECPX.

**The 21CECPX staff includes
Dr. C. Bleasdale – Director.
Mr. Eric Bleasdale – Secretary**

This year was a difficult period. The global economic recession, the declined value of British pound, plus the competition from large US competitors ... all had influences on our business.

We concentrated on the pharmaceuticals (APIs) manufacturing and trading. Particular emphasize to supply R&D needs of the Universities/Institutions/Laboratories/Companies

Business type:

Manufacturing and Global Trading of Pharmaceutical APIs (Active Pharmaceutical Ingredients) and Consumer Goods.

SIC 2441 – Manufacturing basic pharmaceutical products.

SIC 2442 – Manufacturing pharmaceutical preparations.

SIC 5146 – Wholesale of pharmaceutical goods.

SIC 5263 – Other non-store retail sale

Our mission:

High quality, Low cost, Fast delivery, to meet global pharmaceuticals industry / institutions / companies needs.

High quality is the key. Our high quality reputation has been established in the world and recognized by many US and EU famous companies / institutions.

We emphasize meet the special needs of R&D Laboratories.

Our strategy:

21CECPX has a new strategy to develop our B-to-B business. Instead of invest huge amount of capital and time to construct new pharmaceuticals factory in England, we decided to utilize the existing global pharmaceuticals industry force combining with global e-commerce network facilities to develop our business with the fastest effectiveness and minimum cost.

This year we did extensive advertising campaign. We start to build our academic clients database for direct marketing activities.

APIs business:

Our major targeting market for APIs are USA and EU market. We were successful in developing and providing new or rare pharmaceutical APIs. i.e. Paclitaxel, Docetaxel we provide the highest quality products in the world. Many US/EU laboratories use our products as work standard.

Pharmaceuticals R&D Special Service:

The strength of 21CECPX is scientific expertise. We are particular in favour of providing global R&D scientists' needs.


21CEC R&D Special Service was set up specially provide small quantity of pharmaceuticals material for global scientists. We believe the research and development of new medicines will be benefit from our R&D Special Service. However this year we met potential new US competitor in this business field. We are starting to build up our own academic clients database (including all Bioscience PhD/MD degree programs in USA, Canada and Europe) to do direct marketing campaign

Turnover and Profits

During this period, our turnover reached £33,082.00 and our Net Profit (before Tax) is £470.00

We hope that through consistant advertising campaign, our business will obtain more clients and more profit in long term.

Signed by



Dr. C. Bleasdale
Director
21CEC PX PHARM LTD.